Page last updated: 2024-11-12

azadiradione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

azadiradione: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

azadiradione : A tetracyclic triterpenoid that is 4,4,8-trimethylandrosta-1,14-diene substituted by oxo groups at positions 3 and 16, an acetoxy group at position 7 and a furan-3-yl group at position 17. Isolated from Azadirachta indica, it exhibits antimycobacterial and anti-inflammatory activities. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AzadirachtagenusA plant genus of the family MELIACEAE. Members contain azadirachtin A (a limonoid commonly referred to as azadirachtin) and other TRITERPENES. They have been used in PESTICIDES. The old name of Melia azadirachta is very similar to a related plant, MELIA AZEDARACH.[MeSH]MeliaceaeThe mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]
Azadirachta indicaspecies[no description available]MeliaceaeThe mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID12308714
CHEMBL ID1215754
CHEBI ID67280
MeSH IDM0456944

Synonyms (10)

Synonym
CHEMBL1215754
chebi:67280 ,
azadiradione
24-nor-5alpha,13alpha,17alpha-chola-1,14,20,22-tetraene-3,16-dione, 21,23-epoxy-7alpha-hydroxy-4,4,8-trimethyl-,acetate
(5alpha,7alpha,13alpha,17alpha)-17-(furan-3-yl)-4,4,8-trimethyl-3,16-dioxoandrosta-1,14-dien-7-yl acetate
bdbm92410
Q27135739
HY-N9615
[(5r,7r,8r,9r,10r,13s,17r)-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-3,16-dioxo-6,7,9,11,12,17-hexahydro-5h-cyclopenta[a]phenanthren-7-yl] acetate
AKOS040763659

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Azadiradione-treated HD mice brain also exhibited considerable decrease in mutant huntingtin aggregates load and improvement of striatal pathology in comparison with age-matched saline-treated HD controls."( Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
Jana, NR; Kumar, SS; Kumar, V; Mandal, SC; Nelson, VK; Pal, M; Singh, BK; Vatsa, N, 2018
)
2.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antimycobacterial drugA drug used to treat or prevent infections caused by Mycobacteria, a genus of actinobacteria. Aerobic and nonmotile, members of the genus include the pathogens responsible for causing tuberculosis and leprosy.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
limonoidAny triterpenoid that is highly oxygenated and has a prototypical structure either containing or derived from a precursor with a 4,4,8-trimethyl-17-furanylsteroid skeleton. The term 'limonoid' comes from limonin, the first tetranortriterpenoid obtained from citrus bitter principles.
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
cyclic terpene ketoneAn alicyclic ketone in which the carbocyclic ring structure forms part of a terpene skeleton.
furansCompounds containing at least one furan ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Macrophage migration inhibitory factorHomo sapiens (human)IC50 (µMol)41.26670.03803.09109.8000AID1799767
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID499797Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 after 72 hrs by LDH assay2010Journal of natural products, Aug-27, Volume: 73, Issue:8
Antiplasmodial triterpenoids from the fruits of neem, Azadirachta indica.
AID595609Cytotoxicity against human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem).
AID595611Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem).
AID499798Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 72 hrs by LDH assay2010Journal of natural products, Aug-27, Volume: 73, Issue:8
Antiplasmodial triterpenoids from the fruits of neem, Azadirachta indica.
AID713894Antimycobacterial activity against Mycobacterium tuberculosis H37Ra2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in antitubercular natural products.
AID1110753Antifeedant activity against larvae of Spodoptera litura in castor leaves relative to control2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Insect antifeedant activity of tetranortriterpenoids from the Rutales. A perusal of structural relations.
AID595610Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem).
AID595613Cytotoxicity against human CRL1579 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem).
AID595612Cytotoxicity against human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem).
AID1799767Tautomerase Activity Assay from Article 10.1074/jbc.M112.341321: \\Novel Anti-inflammatory Activity of Epoxyazadiradione against Macrophage Migration Inhibitory Factor: INHIBITION OF TAUTOMERASE AND PROINFLAMMATORY ACTIVITIES OF MACROPHAGE MIGRATION INHIBI2012The Journal of biological chemistry, Jul-13, Volume: 287, Issue:29
Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's11 (68.75)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.74 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]